(Q38031028)

27 August 2017

title

Renal toxicity associated with antiretroviral therapy (English)

1 reference

27 August 2017

main subject

anti-retroviral agent

0 references

renal toxicity

0 references

author name string

Leonardo Calza

series ordinal

1

1 reference

27 August 2017

publication date

1 July 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

13

1 reference

27 August 2017

issue

4

1 reference

27 August 2017

page(s)

189-211

1 reference

Kidney disease in patients with HIV infection and AIDS.

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

HIV-associated nephropathy: epidemiology, pathogenesis, diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

CD4+ count-guided interruption of antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Interruption of antiretroviral therapy is associated with increased plasma cystatin C

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

HIV infection, inflammation, immunosenescence, and aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Early immune senescence in HIV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

21 January 2018

HIV and CKD epidemiology

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Renal issues in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

The nephrotoxic effects of HAART.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Renal function with use of a tenofovir-containing initial antiretroviral regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Biomarkers of impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Progressive renal tubular dysfunction associated with long-term use of tenofovir DF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Urinary beta2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Urinary cystatin C can improve the renal safety follow-up of tenofovir-treated patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Tenofovir-associated renal and bone toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Renal function in Tenofovir-exposed and Tenofovir-unexposed patients receiving highly active antiretroviral therapy in the HIV Outpatient Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Spectrum of chronic kidney disease in HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Prevalence and factors associated with renal dysfunction among HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE st

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Tenofovir renal toxicity targets mitochondria of renal proximal tubules

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Fanconi syndrome associated with didanosine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Crystalluria and urinary tract abnormalities associated with indinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Risk factors for urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: the ATHENA cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Lopinavir-ritonavir (Kaletra) and lithiasis: seven cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

A new equation to estimate glomerular filtration rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Maraviroc for previously treated patients with R5 HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Cystatin C level as a marker of kidney function in human immunodeficiency virus infection: the FRAM study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Validation of estimated renal function measurements compared with the isotopic glomerular filtration rate in an HIV-infected cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

Determination of Kidney Function Before Tenofovir Initiation: Four-Fold Difference in Need of Tenofovir Dose Reduction Depending on Method Used

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1304-189

21 January 2018

Identifiers

DOI

10.1310/HCT1304-189

1 reference

27 August 2017

1 reference